שווי פעילות לרווח לפני ריבית, מסים ופחת Iterum Therapeutics (ITRM)

The linear price action on the chart for Iterum Therapeutics plc (ITRM) captures the EV/EBITDA ratio at 0.00. The business remains resilient to market volatility, as demand for antibiotics is independent of economic cycles and macro shocks. Iterum Therapeutics plc (ITRM) is implementing oral treatments to combat resistant infections, thereby reducing the burden on inpatient facilities. The expected FDA verdict will enable the creation of a closed clinic network and the launch of full-scale commercial operations for its drugs.

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization, determining the payback period for investments in capital-intensive assets. For Iterum Therapeutics plc (ITRM), which lacks a stable cash flow due to the project-based nature of antibiotic development, the company's EV/EBITDA multiple reflects a highly speculative valuation, confirming the asset's dependence on future regulatory approvals.